INmune Bio (INMB) Projected to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

INmune Bio Stock Down 3.1%

NASDAQ INMB opened at $1.24 on Thursday. The stock has a market capitalization of $32.96 million, a PE ratio of -0.58 and a beta of 0.77. INmune Bio has a 12-month low of $1.16 and a 12-month high of $11.64. The company has a 50 day moving average price of $1.47 and a two-hundred day moving average price of $1.69.

Analysts Set New Price Targets

INMB has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Trading of INmune Bio

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new position in INmune Bio in the 1st quarter valued at $142,000. Rhumbline Advisers lifted its position in INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after acquiring an additional 2,409 shares during the last quarter. Royal Bank of Canada lifted its position in INmune Bio by 44.8% during the 1st quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after acquiring an additional 9,236 shares during the last quarter. Geode Capital Management LLC boosted its holdings in INmune Bio by 6.9% during the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock valued at $901,000 after acquiring an additional 25,069 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in INmune Bio during the third quarter valued at about $30,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.